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We sought to examine the pathogenic role of excessive
VEGF-A expression in podocytes, since it has been reported
that diabetic nephropathy and other glomerular diseases are
associated with increased VEGF-A expression. The induction
of podocyte-specific VEGF164 overexpression in adult
transgenic mice led to proteinuria, glomerulomegaly,
glomerular basement membrane thickening, mesangial
expansion, loss of slit diaphragms, and podocyte effacement.
When doxycycline-mediated VEGF164 was stopped, these
abnormalities reversed. These findings were associated with
reversible downregulation of metalloproteinase 9 and
nephrin expression. Using transmission electron microscopy,
we established that VEGF-A receptor-2 (VEGFR2) was
expressed in podocytes and glomerular endothelial cells. We
also found that VEGF164 induced VEGFR2 phosphorylation in
podocytes. Further, we were able to co-immunoprecipitate
VEGFR2 and nephrin using whole kidney lysates, confirming
interaction in vivo. This implies that autocrine and paracrine
VEGF-A signaling through VEGFR2 occurs in podocytes and
may mediate the glomerular phenotype caused by VEGF164
overexpression. Thus, we suggest that podocyte VEGF164
overexpression in adult mice is sufficient to induce
glomerular filtration barrier structural and functional
abnormalities similar to those present in murine diabetic
nephropathy.
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Vascular endothelial growth factor-A (VEGF-A) is the
major determinant and regulator of angiogenesis.1 Inactiva-
tion of a single VEGF-A allele causes embryonic lethality,
showing that threshold levels of VEGF-A signaling are
required for maintaining the differentiation, correct assem-
bly, and maturation of endothelial cells.2,3 Similarly,
podocyte-specific deletion of VEGF-A in mice showed
that over 50% allelic dose of VEGF-A is required for develop-
ment and maintenance of a functional glomerular filtra-
tion barrier.4 Conversely, massive VEGF-A overexpression
in podocytes caused glomerular collapse and perinatal
lethality.4 These developmental phenotypes precluded the
analysis of the role of VEGF-A expression in adult kidney
disorders.
Excessive renal VEGF-A expression has been documented
in diabetic nephropathy and glomerular diseases, which
are the leading causes of end-stage renal disease in humans.5
However, it is not clear whether changes in VEGF-A
expression are a cause, a consequence, or a bystander in
kidney diseases.5–7 Anti-VEGF antibody therapy reduced the
severity of diabetic nephropathy in rodents,8–10 whereas it
induced hypertension and glomerular disease in cancer
patients.11,12 VEGF-A was shown to accelerate the resolution
of experimental glomerulonephritis, ameliorate cyclosporine
nephropathy, and protect remnant kidneys.13 Our previous
in vitro studies showed that VEGF-A attracts endothelial cells
to developing glomeruli,14 promotes podocyte survival
through an autocrine pathway involving VEGF receptor-2
(VEGFR2), induces podocin upregulation and its association
with CD2AP.15 It is unclear whether autocrine podocyte
VEGF-A signaling occurs in vivo. In this study we report that
induction of moderate podocyte VEGF164 overexpression
in adult mice causes a glomerular disease characterized by
glomerulomegaly, mesangial proliferation, glomerular base-
ment membrane (GBM) thickening, loss of slit diaphragms,
podocyte effacement, and proteinuria in the absence of
a diabetic milieu, which is reversible upon removal of
doxycycline, and we provide insight into its molecular
mechanism.
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RESULTS
Inducible podocyte VEGF164 overexpression in vivo
To analyze the pathogenic role of VEGF-A in glomerular
disease and circumvent early lethality, we developed an indu-
cible, podocyte-specific, tetracycline-regulated VEGF164 over-
expression model (podocin-rtTA:tet-O-VEGF164) by breeding
podocin-rtTA mice16 with tet-O-VEGF164 mice.
17 In podocin-
rtTA:tet-O-VEGF164 mice, immunoreactive VEGF-A localized
to podocytes was increased upon doxycycline induction
(Supplementary Figure S1a). VEGF-A protein in whole kidney
lysate measured by enzyme-linked immunosorbent assay
increased twofold in doxycycline-treated podocin-rtTA:tet-O-
VEGF164 mice (0.1±0.005 vs 0.2±0.01 pg/mg protein, dox,
n¼ 8 vs þ dox, n¼ 13, Po0.05, Supplementary Figure S1b),
whereas urine VEGF-A increased 15-fold (13.1±1.2 vs
206.7±110.2 pg/day, dox, n¼ 9 vs þ dox, n¼ 6, Po0.05).
Podocyte VEGF164 overexpression causes proteinuria
Adult mice overexpressing podocyte VEGF164 for 1 month
developed proteinuria (TOPO þ dox, Figure 1a–c). In
contrast, age-matched uninduced podocin-rtTA:tet-O-
VEGF164 mice (TOPO dox) did not develop proteinuria
(Figure 1a and c), nor did single transgenic mice receiving
doxycycline (CON þ dox, Figure 1a), indicating that neither
the transgenes nor the doxycycline per se caused proteinuria.
Notably, VEGF164-induced proteinuria was reversible 2 weeks
after doxycycline removal from the diet (Figure 1b and c),
suggesting a cause-and-effect relationship between VEGF164
and proteinuria. Moreover, proteinuria positively correlated
with increased kidney VEGF-A content in mice overexpres-
sing VEGF164 (Figure 1d), but did not correlate with VEGF-A
plasma levels, which remained unchanged (24±1.9 vs
22±2.2 pg/ml, dox, n¼ 9 vs þ dox, n¼ 12, P¼NS),
suggesting that podocytes are not the main source of
circulating VEGF-A, and that podocyte VEGF164 effects are
local rather than systemic. VEGF164-induced albuminuria
was detected by immunoblotting (Figure 1c), and quantified
by enzyme-linked immunosorbent assay (Figure 1e). The
urine albumin/creatinine ratio was 4- to 16-fold higher in
doxycycline-induced than in uninduced podocin-rtTA:tet-O-
VEGF164 mice (P¼ 0.0027, Figure 1e), consistent with the
data obtained by dipstick and western analysis.
Podocyte VEGF164 overexpression induces glomerulomegaly
We examined the morphologic changes associated with
VEGF164-induced proteinuria. Podocyte VEGF164 overexpres-
sion in adult mice induced glomerular enlargement,
thickened GBM, and mild mesangial expansion (Figure 2a,
Supplementary Figure S2a). Morphometric analysis confir-
med VEGF164-induced glomerulomegaly, with 1.8- to 2-fold
increase in mean glomerular volume, which was partially
reversible upon cessation of VEGF164 overexpression (Figure
2a and b), and showed a right shift in the distribution
of glomerular volumes indicating widespread enlargement
and increased size heterogeneity (Figure 2b) and increased
mesangial matrix area (Supplementary Figure S2a).
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Figure 1 |Podocyte VEGF164 overexpression in adult mice causes proteinuria. (a) Podocin-rtTA:tet-O-VEGF164 adult mice induced with
doxycycline for 1 month (TOPO þdox) develop proteinuria, as compared with uninduced podocin-rtTA:tet-O-VEGF164 mice (TOPO dox)
and single transgenic controls receiving doxycycline or not (CON þdox and CON dox). (b) Proteinuria is reversible upon removal
of doxycycline induction (TOPO þdox vs TOPO ±dox). (c) Albumin immunoblot showing albuminuria in induced TOPO þdox, no
albuminuria in uninduced TOPO dox, and minimal albuminuria in TOPO ±dox. (d) Proteinuria has a significant positive correlation with
kidney vascular endothelial growth factor-A (VEGF-A) content in induced TOPO mice (þdox), whereas it does not in uninduced TOPO mice
(dox). (e) Urine albumin/creatinine ratio (mg/mg) in TOPO þdox (n¼ 8) is more than fourfold higher than in TOPO dox (n¼ 6). Notice
that the scale on the right side of the figure is depicted to include the sample labeled (o), which showed 1562 mg/mg, and horizontal bars
depict the median for each experimental group. In all graphs *indicates Po0.05 TOPO þdox vs TOPO dox mice, and TOPO þdox vs
TOPO ±dox mice.
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Podocyte VEGF164 overexpression induces GBM thickening
and podocyte effacement in adult mice
To further evaluate these glomerular abnormalities, kidneys
were examined by transmission electron microscopy (TEM)
1 month after VEGF164 transgene induction. TEM revealed
a dramatic increase in GBM thickness and irregularity,
and absence of lamina rara interna and externa in kidneys
overexpressing VEGF164 (Figure 2c, panels C and F) when
compared with controls: podocin-rtTA:tet-O-VEGF164 with-
out doxycycline (Figure 2c, panels I and L) and single
transgenics on doxycycline (Figure 2c, panels A, B, D, and E)
or off doxycycline (Figure 2c, panels G, H, J, and K),
which were all normal. In addition to the GBM changes,
doxycycline-induced mice showed partial foot process
effacement and fusion (Figure 2c, panels C and F), and
increased mesangial matrix deposition (Supplementary
Figure S2b). These ultrastructural changes were observed
in all kidneys examined and involved all glomeruli (nX3/
kidney). Surprisingly, no endothelial cell swelling or damage
was observed by TEM and fenestrations were intact in
kidneys from doxycycline-treated mice.
Morphometric analysis showed a twofold increase in
GBM thickness in induced podocin-rtTA:tet-O-VEGF164 mice
(TOPO þ dox) when compared with uninduced controls
(TOPO dox, Figure 3a). Podocyte abnormalities were
apparent along most of the GBM length, and resulted in
an average 66% increase in foot process width (268±5 vs
445±28 nm, TOPO dox vs TOPO þ dox, Po0.001),
a 40% decrease in slit diaphragm density, and a threefold
increase in occluding junction density (Figure 3b and c).
VEGF164-induced GBM, podocyte, and mesangial abnor-
malities were reversible at 2 weeks after doxycycline removal,
underscoring the cause-and-effect relationship between
excess podocyte VEGF-A and development of glomerular
disease (Figure 3a–d, Supplementary Figure S1b).
We determined that random non-fasting plasma glucose
levels were normal in podocin-rtTA:tet-O-VEGF164 on doxy-
cycline (157±24mg/dl, n¼ 8), and not different from
glucose levels in uninduced mice (179±11mg/dl n¼ 9,
P¼NS). We also determined that systolic blood pressure
was normal in doxycycline-induced and uninduced podocin-
rtTA:tet-O-VEGF164 adult mice (104±5mmHg, n¼ 5 vs
99±5mmHg, n¼ 5, P¼NS).
Podocyte VEGF164 overexpression decreases renal expression
of matrix metalloproteinase 9 (MMP-9) and nephrin
GBM thickening and podocyte effacement are suggestive of
abnormal GBM composition and altered podocyte protein
expression,18 respectively. Thus, we examined the expression
of major GBM components and podocyte-specific proteins.
We determined that collagen IV and laminin had similar
localization in the glomerular and tubular GBM of mice
overexpressing podocyte VEGF164 and uninduced controls
(Figure 4a). Real-time PCR revealed that collagen IV a3,
a4, a5, and laminin a1, a5, and b1 kidney mRNA levels
were unchanged after 1 month of VEGF164 overexpression
(Figure 4b). Similarly, Ndst1 and 2 and syndecan were
unchanged (Figure 4b). Integrin a3 and a5 kidney mRNA
levels did not change significantly, whereas integrin b1
mRNA was significantly decreased after 1 month of VEGF164
overexpression (Figure 4b). However, b1-integrin protein
levels were not significantly altered (data not shown). In
contrast, total kidney MMP-9 mRNA, protein level and
activity, as well as glomerular immunoreactivity were
decreased significantly in mice overexpressing podocyte
VEGF164 (Figure 4b, c, f, and g). MMP-9 downregulation
was abrogated by removal of VEGF164 induction (Figure 4c).
As doxycycline is a known inhibitor of metalloproteinases,19
we also examined the effect of doxycycline on renal MMP-9
expression in single transgenic mice (CON þ dox). MMP-9
was not altered in single transgenics receiving doxycycline
(Figure 4c and g). Hence, VEGF164 overexpression specifically
induced downregulation of MMP-9 expression and activity
(Figure 5c and g). MMP-2 protein level remained unchanged in
mice overexpressing podocyte VEGF164 (Figure 5d). Collectively,
these data suggest that podocyte VEGF164 overexpression in
adult mice reduces GBM turnover, as implied by the reversible
decrease in MMP-9 mRNA, protein, and activity levels.
Podocyte VEGF164 overexpression induced a significant
decrease in nephrin mRNA, protein levels, and immunor-
eactivity, whereas nephrin phosphorylation increased them
(Figure 4b, e, and f). Removal of doxycycline induction
abrogated nephrin downregulation and phosphorylation,
underscoring the cause–effect relationship between VEGF164
overexpression and nephrin dysregulation (Figure 4e). In
contrast, podocin expression levels remained unchanged
(data not shown), suggesting that VEGF164 overexpression
does not cause overall dysregulation of slit diaphragm
proteins or podocyte loss. The concomitant reversibility
of nephrin downregulation and phosphorylation, podocyte
effacement, and proteinuria upon removal of VEGF164
induction suggests that nephrin dysregulation is the mole-
cular basis for the VEGF164-induced podocyte effacement.
Podocytes express VEGFR2, and VEGFR2 interacts with
nephrin in vivo
We next analyzed whether the ultrastructural changes
observed in podocytes from doxycycline-induced podocin-
rtTA:tet-O-VEGF164 mice were caused by autocrine VEGF164
signaling. We identified the glomerular cell types expressing
VEGFR2, the main VEGF-A signaling receptor, by TEM and
histochemistry in adult Flk-1þ / mice, which carry one Flk-1
allele with a LacZ gene in-frame insertion.20 As shown in
Figure 5a–c, Flk-1þ / mice express b-Gal in lieu of VEGFR2
in both glomerular endothelial cells and podocytes. More-
over, b-Gal electron-dense precipitates were observed in the
podocyte cell body (Figure 5b) and foot processes, closely
adjacent to slit diaphragms (Figure 5c). Neighboring
mesangial cells were mostly devoid of b-Gal electron-dense
precipitates, and tubular cells, as well as unstained samples
from the same kidneys were negative (Figure 5d). Immuno-
electron microscopy confirmed VEGFR2 protein expression
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in podocyte foot processes and cell bodies as well as in
endothelial cells (Figure 5e and f). Tyrosine phosphorylated
VEGFR2 was detected in glomeruli from control mice but
rarely colocalized with nephrin (Figure 5g, dox), whereas
phosphorylated VEGFR2 was increased and colocalized with
nephrin in podocytes from VEGF164-overexpressing mice
(Figure 5g, þ dox), suggesting that increased VEGF164 signals
induced VEGFR2 phosphorylation in podocytes.
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To examine a possible crosstalk between VEGF-A and
nephrin signaling pathways we performed immunoprecipita-
tion experiments. VEGFR2 co-immunoprecipitated with
nephrin in kidney lysates (Figure 5h), indicating that
VEGFR2 and nephrin interact in vivo. Moreover, purified
FLAG-tagged VEGFR2 protein associated with endogenous
nephrin (Figure 5i), confirming the interaction in vitro.
Together, our findings show that VEGFR2 is expressed in
podocytes and interacts with nephrin in vivo, suggesting that
the phenotype induced by podocyte VEGF164 overexpression
results from autocrine and paracrine signals, which involve
nephrin and MMP-9 dysregulation, nephrin–VEGFR2 inter-
action, and VEGF164-induced phosphorylation of both
proteins in vivo.
Figure 2 |Podocyte VEGF164 overexpression in adult mice causes glomerulomegaly, GBM thickening, podocyte effacement, and
SD loss. (a) Gomorri’s silver methenamine stain in podocin-rtTA:tet-O-VEGF164 uninduced mice (TOPO dox), mice induced for 1 month
(TOPO þdox), and mice induced for 1 month, and then off induction for 2 weeks (TOPO ±dox), showing enlarged glomeruli with thicker
GBM in TOPO þdox mice, and regression of these changes in TOPO ±dox mice. (b) Morphometric analysis of glomerular size: podocin-
rtTA:tet-O-VEGF164 induced mice (TOPO þdox) had approximately twofold larger glomerular volume than uninduced mice (TOPO dox)
and controls (CON þdox); the glomerular enlargement partially subsided after 2 weeks off doxycycline (TOPO ±dox). The distribution of
glomerular volumes showed significantly increased size heterogeneity in induced mice (TOPO þdox), in addition to overall enlargement, as
shown by the mean±s.e.m. difference (inset). *Po0.05, TOPO þdox vs TOPO dox-treated mice. (c) TEM showing kidneys from podocin-
rtTA mice (left panels), tet-O-VEGF164 mice (middle panels), and podocin-rtTA:tet-O-VEGF164 mice (right panels) induced with doxycycline for
1 month (þdox), and uninduced (dox). All left and middle panels (single transgenics) show normal kidney ultrastructure, whereas induced
podocin-rtTA:tet-O-VEGF164 kidneys (top panels C and F) show diffuse GBM thickening (*), mesangial expansion, and podocyte effacement.
Notice that uninduced podocin-rtTA:tet-O-VEGF164 kidneys are normal (bottom panels I and L). Scale bars¼ 1 mm in panels A–C and G–I, and
¼ 200 nm in panels D–F and J–L. EC, endothelial cell; efp, effaced foot process, fp, foot process; GBM, glomerular basement membrane;
P, podocyte; RBC, red blood cell; SD, slit diaphragm; TEM, transmission electron microscopy.
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Figure 3 |Ultrastructural abnormalities caused by podocyte VEGF164 overexpression are reversible. Morphometric comparisons were
made among podocin-rtTA:tet-O-VEGF164 mice uninduced, induced, and that in which induction was removed to test reversibility (TOPO
dox, TOPO þdox, and TOPO ±dox, respectively). (a) Glomerular basement membrane (GBM) thickness expressed in nm, showing a
twofold increase in mice overexpressing VEGF164; (b) foot process width, a measure of podocyte effacement, increased 460% in mice
overexpressing VEGF164; (c) density of podocyte foot process interactions (‘pores’), measured as the number of slit diaphragms (SD) or
occluding junctions (OJ) per mm of GBM length, showing mirror image changes: increase in OJ and decrease in SD in mice overexpressing
VEGF164. Changes in all these morphometric parameters were reversible upon removal of VEGF164 induction (TOPO±dox). Total number of
measurements (n) for each parameter in TOPO dox, TOPO þdox, and TOPO±dox mice were as follows: GBM thickness: n¼ 241, 431, and
272; foot process width: n¼ 422, 584, and 311; SD: n¼ 378, 409, and 254; and OJ: n¼ 32, 165, and 40. *Po0.05, TOPO þdox vs TOPO dox
or TOPO±dox; **Po0.05, TOPO±dox vs TOPO dox. (d) Representative transmission electron microscopy (TEM) showing the reversible
ultrastructural abnormalities quantified in (a–c), large * points out the thickened GBM. Notice the lack of endothelial cell abnormalities, scale
bars¼ 200 nm.
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DISCUSSION
In this study we show that podocyte VEGF164 overexpression
in adult mice results in proteinuria and a distinct glomerular
phenotype characterized by glomerulomegaly, mesangial
expansion, podocyte foot process effacement, and thickened
GBM. The cause-and-effect relationship between podocyte
VEGF164 overexpression and glomerular phenotype was
clearly shown by the reversibility of the functional,
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Figure 4 |Podocyte VEGF164 induction in adult mice decreases matrix metalloproteinase 9 (MMP-9) and nephrin. (a) Fluorescent
immunohistochemistry showing that collagen IV and laminin are normally localized in mice overexpressing VEGF164. (b) Real-time PCR
data showing relative mRNA expression of glomerular basement membrane (GBM) components and nephrin in mice overexpressing
VEGF164/uninduced mice of the same genotype (TOPO þ dox/ TOPO dox), using pooled RNA from 9 and 8 mice, respectively. Data are
expressed as mean fold changes±s.e.m., n¼ 3, *Po0.05. (c) Western blot showing decreased MMP-9 protein in mice overexpressing
VEGF164 (TOPO þdox) vs uninduced mice (TOPO dox), controls are single transgenic on dox (CON þdox), MMP-9 downregulation is
reversible (TOPO±dox). (d) Western blot showing no change in MMP-2 levels in TOPO þdox, TOPO dox, and TOPO ±dox. (e) Western
blots showing decreased nephrin expression and enhanced phosphorylation in VEGF164-overexpressing (TOPO þdox) vs uninduced
kidneys (TOPO dox), nephrin dysregulation is reversible (TOPO±dox). In (c–e) whole kidney lysate was pooled from 13 (TOPO þdox) and
8 (TOPO dox) podocin-rtTA:tet-O-VEGF164 mice, 8 single transgenic mice (CON þdox), and 6 podocin-rtTA:tet-O-VEGF164 mice on
doxycycline for 1 month and off for 2 weeks (TOPO ±dox). Actin and tubulin blots are shown to document equal loading. Densitometric
analysis shows mean±s.e.m. fold change in arbritrary units when compared with controls, nX4. (f) MMP-9 and nephrin
immunohistochemistry. Podocin-rtTA:tet-O-VEGF164 induced (þdox) showed decreased MMP-9 and nephrin when compared with
uninduced mice (dox), with unchanged localization, scale bars¼ 20mm. (g) MMP-9 zymogram shows decreased MMP-9 activity in kidneys
overexpressing VEGF164 (TOPO þ dox), positive control¼ recombinant mouse MMP-9 (2.5 ng).
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morphologic, and molecular changes observed upon removal
of doxycycline.
Podocyte VEGF164 overexpression-induced albuminuria
was 4- to 16-fold higher than control, the proteinuria had a
significant positive correlation with the kidney VEGF-A
content, and most importantly, was fully reversible upon
cessation of doxycycline. The association of glomerulome-
galy, mildly increased mesangial matrix, GBM thickening,
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Figure 5 |Vascular endothelial growth factor receptor-2 (VEGFR2) is expressed in podocytes and endothelial cells. (a) Transmission
electron microscopy (TEM) of LacZ-stained kidneys from adult Flk-1þ / LacZ mice showing extensive b-Gal electron-dense deposits in
glomerular capillaries and in podocytes, scale bar¼ 1mm; (b) b-Gal electron deposits in a podocyte body, scale bar¼ 500nm; and (c) b-Gal
electron deposits in foot processes, scale bar¼ 200nm. (d) TEM of the same kidney, not stained for LacZ (negative control), scale bar¼ 200nm.
(e) Immunogold staining for VEGFR2 showing immunoreactive VEGFR2 in foot processes, scale bar¼ 200nm, inset: higher magnification of
two foot processes flanking a slit diaphragm showing immunogold VEGFR2 staining; (f) immunoreactive VEGFR2 in podocyte body and
endothelial cell, scale bar¼ 500nm. cap, capillary lumen; EC, endothelial cell; fp, foot process; P, podocyte. 4b Gal electron-dense deposits.
(g) VEGF164 overexpression induces VEGFR2 phosphorylation in podocytes: immunoreactive phosphorylated (P)-VEGFR2 (green) is increased in
glomeruli from VEGF164-overexpressing mice (þdox) as compared with uninduced glomeruli (dox); nephrin (red) and P-VEGFR2 (green)
colocalize (yellow) in podocytes from VEGF164-overexpressing mice (þdox). Scale bars¼ 20mm. (h) VEGFR2 and nephrin interact in vivo:
immunoprecipitation (IP) with anti-VEGFR2 (VR2) antibody followed by western blotting (WB) with anti-nephrin antibody and VEGFR2 antibody
showing co-immunoprecipitation; reverse co-IP experiment: IP with anti-nephrin antibody, followed by WB with anti-nephrin and anti-VEGFR2
antibody; VR2, VEGFR2; NS, normal rabbit serum (IP negative control); input, whole kidney lysate. (i) VEGFR2 and nephrin interact in vitro: IP
with anti-nephrin, followed by WB with anti-Flag and anti-nephrin antibodies, showing that nephrin immunoprecipitate interacts with purified
Flag-tagged VEGFR2; input 1, whole kidney lysate; input 2, Flag-VEGFR2 transfected COS cell lysate.
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and foot process widening with loss of slit diaphragms
induced by podocyte VEGF164 overexpression in adult mice
were similar to the classic glomerular abnormalities reported
in early diabetic nephropathy in humans and rodents.18,21
However, normal glucose levels in mice overexpressing
podocyte VEGF164 ruled out diabetes mellitus, and the
absence of hypertension ruled out VEGF164-induced hyper-
tensive nephrosclerosis.
The dramatic GBM thickening and the lack of significant
endothelial cell damage observed by TEM in adult mice
overexpressing podocyte VEGF164 clearly differ from the
glomerular phenotypes described in VEGF-induced collap-
sing glomerulopathy,4 and a rabbit model of liver and kidney
VEGF overexpression,22 probably because of timing of VEGF
overexpression, transgene dosage, and species differences.
Our data show pathogenic effects of moderately increased
podocyte VEGF164 in adult mice causing a distinct GBM and
podocyte phenotype that spares the glomerular endothelial
cells. Furthermore, we show that the molecular mechanism
responsible for this phenotype involves decreased expression
of collagenase MMP-9 and nephrin.
We provide evidence of decreased MMP-9 expression and
activity in podocyte VEGF164-overexpressing mice. As
doxycycline is a known inhibitor of metalloproteinases,19,23
we also examined the effect of doxycycline on renal MMP-2
and MMP-9 expression in single transgenic mice. We deter-
mined that downregulation of MMP-9 expression is clearly
induced by VEGF164 overexpression, as it was abrogated by
removal of VEGF164 transgene induction, and remained
stable in all control mice receiving doxycycline. Surprisingly,
MMP-2 protein expression levels were not altered in mice
overexpressing podocyte VEGF164. Taken together, these
findings suggest that podocyte VEGF164 overexpression
in vivo reduces GBM turnover, rather than enhancing synthesis
of GBM components such as collagen IV and perlecan, as
suggested by in vitro data.24,25 Alternatively, the thickened
GBM could be due to deposition of another collagen type
not normally expressed in the GBM, such as collagen
type III,18,26,27 but our quantitative reverse transcriptase-PCR
data do not support this possibility (data not shown).
Consistent with partial podocyte effacement and fusion,
we detected downregulation of nephrin expression and
increased nephrin phosphorylation in podocyte VEGF164-
overexpressing kidneys, which were reversible upon doxy-
cycline removal, suggesting that increased VEGF-A signaling
alters the nephrin signaling complex function, and thereby
podocyte phenotype. Decreased nephrin expression has been
described in multiple human proteinuric diseases,28,29
including diabetic nephropathy.18,21,30 Increased nephrin
phosphorylation has been observed during development
and in a rodent model of foot process effacement,31 whereas
decreased nephrin phosphorylation was reported in rat
puromycin aminonucleoside nephrosis and in human mini-
mal change disease.32 As deletion of Nck, an adaptor protein
that selectively binds to phosphorylated nephrin, leads to
congenital nephrotic syndrome,33 it seems that signals
mediated by phosphorylated nephrin are necessary for the
establishment of mature podocyte foot processes and slit
diaphragms, whereas the role of dysregulated nephrin
phosphorylation in postnatal glomerular diseases is less clear.
We sought to identify the glomerular cell types expressing
VEGFR2, the main VEGF-A signaling receptor,34–36 to
understand whether the ultrastructural abnormalities and
the associated nephrin dysregulation observed in podocyte
VEGF164-overexpressing mice were caused by autocrine or
paracrine signaling. Using TEM combined with either b-Gal
staining37 or immunogold staining, we detected VEGFR2
expression in glomerular endothelial cells and in podocytes,
extensively distributed in the cell body, foot processes, and
close to slit diaphgrams. Furthermore, increased activated
VEGFR2 was detected by immunohistochemistry in podo-
cytes from mice overexpressing VEGF164, suggesting that
increased VEGF164 signals induced VEGFR2 phosphorylation
in situ. Localization of VEGFR2, but not VEGFR1, to
podocytes by immunogold staining was recently reported.38
We identified a novel interaction between endogenous
VEGFR2 and nephrin by co-immunoprecipitation in vivo,
and confirmed the association between purified Flag-tagged
mouse VEGFR2 and endogenous nephrin from kidney
lysates, suggesting a crosstalk between VEGF-A and nephrin
pathways. As nephrin expression is limited to podocytes,
this interaction independently confirms the expression of
VEGFR2 in podocytes. Moreover, our observation that
podocyte VEGF164 overexpression induced nephrin phos-
phorylation supports the notion that VEGFR2–nephrin
interaction may have functional relevance, and represents a
novel mechanism for crosstalk between VEGF-A and nephrin
signaling pathways. Collectively, our findings suggest that
podocyte VEGF164 signaling is both autocrine and paracrine,
and provide a plausible interpretation for the podocyte
phenotypic changes and the nephrin dysregulation observed
in podocyte VEGF164-overexpressing kidneys. Further studies
are warranted to define the biochemistry of VEGFR2–nephrin
interaction, and how it modulates nephrin signaling. As
Flk-1-null mice are embryonic lethal and heterozygous mice
do not have a vascular or glomerular phenotype,20 only a
complete, inducible, and podocyte-specific VEGFR2 knock-
out would definitively elucidate whether the mechanism
proposed in this study is required for the integrity of the
glomerular filtration barrier. Our studies do not exclude
possible effects of VEGF164 overexpression through VEGFR1,
which is considered to exert an effect as a negative modulator
of VEGFR2 signaling in most tissues by sequestering VEGF-A
ligand, and thereby decreasing VEGFR2 activation, although
the mechanisms involved remain controversial.34–36
In summary, induction of podocyte VEGF164 overexpres-
sion in the adult mouse causes proteinuric glomerular disease
that mimics early diabetic nephropathy, in the absence of a
diabetic milieu. Reversibility of these changes upon removal
of doxycycline provides proof of principle of the causal
relationship. Our findings are consistent with an autocrine
pathogenic role of increased podocyte VEGF-A in this
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process, involving nephrin and MMP-9 dysregulation,
nephrin–VEGFR2 interaction, and VEGF164-induced phos-
phorylation of both proteins in vivo. Our inducible model
should prove useful to identify the downstream mechanisms
of VEGF-induced glomerular disease in adult mice, and to
test therapeutic interventions.
MATERIALS AND METHODS
Inducible, podocyte-specific VEGF164 overexpression in mice
All mouse protocols were approved by the Committee for Animal
Use and Experimentation of Albert Einstein College of Medicine. We
generated tetracycline-regulated transgenic mice (podocin-rtTA:tet-
O-VEGF164) that overexpress VEGF-A in podocytes upon induction
with doxycycline by breeding podocin-rtTA mice16 with tet-O-
VEGF164 mice,
17 which carry FVB background. Transgenic mice
were genotyped by reverse transcriptase-PCR using reported
primers.16,17 Adult podocin-rtTA:tet-O-VEGF164 mice (2–3 months
old) received doxycycline (0.625mg/g chow, Harlen-Teklar,
Madison, WI, USA) for 1 month (TOPO þ dox, n¼ 14).
Uninduced podocin-rtTA:tet-O-VEGF164 (TOPO dox, n¼ 9),
induced single transgenics (CON þ dox, n¼ 4), and uninduced
single transgenics (CON dox, n¼ 4) served as controls. Additional
podocin-rtTA:tet-O-VEGF164 mice were induced with doxycycline for
1 month, and then switched to regular diet for 2 weeks to examine
the reversibility of VEGF164-induced changes (TOPO±dox, n¼ 6).
Blood pressure was measured using the Coda Noninvasive-Blood-
Pressure-System (Kent Scientific, Torrington, CT, USA).39
Proteinuria and VEGF-A analysis
Mice were anesthetized with ketamine, and blood and urine samples
were obtained from venous and bladder puncture, kidneys were
harvested for phenotype analysis, and mice were then killed by
exsanguination. Urinary creatinine was measured using a colori-
metric assay (Oxford Biomedical Research, Oxford, MI, USA).
Albuminuria was assessed by dipstick (Albustix; Bayer, Elkhart, IN,
USA), enzyme-linked immunosorbent assay (Albuwell; Exocell,
Philadelphia, PA, USA), and immunoblotting. Urine samples
(normalized for creatinine) were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and immunoblotted with
anti-bovine serum albumin antibody (Upstate Biotechnology, Lake
Placid, NY, USA). Serum and whole kidney VEGF-A were measured
by enzyme-linked immunosorbent assay (mVEGF-A, R&D, Minnea-
polis, MN, USA), following the manufacturer’s protocol. Serum
glucose was measured by glucose oxidase biosensor (One-Touch-
Ultra-2 Blood Glucose-Meter, LifeScan, Milpitas, CA, USA).
Histology and morphometry
Kidneys were processed for light and transmission electron micro-
scopy or frozen in isopentane and mounted in optimum cutting
temperature compound (Sakura, Torrance, CA, USA). Hematoxylin/
eosin and Gomorri’s silver methenamine staining were performed.
Morphometric analysis. Glomerular diameters were measured
in 135±5 gloms/section at  400 magnification. Glomerular
volume was determined as Gv¼ b/k.(p.r2)3/2, where b¼ 1.38 is the
shape coefficient for spheres, k¼ 1.1 is the size distribution
coefficient, and (p.r2) is the glomerular area.26 Measurements were
carried out in four mice per group. Slit diaphragms, foot process
width, and GBM thickness were measured on TEM scans using
Image J, Bethesda, MD, USA (NIH). Measurements were made
perpendicular to the axis of the GBM every 500 nm on 30–50 mm
GBM length/5K images. Occluding junctions and slit diaphragms
were counted and normalized to GBM length (mm), termed ‘OJ or
SD density’. TEM measurements were carried out in five mice per
group; counts for each parameter are depicted in figure legends.
Immunohistochemistry
Kidneys were embedded in optimum cutting temperature com-
pound, and snap-frozen in dry ice/isopentane or fixed in formalin
and paraffin embedded. Paraffin sections were deparaffinized,
incubated in 10mM citrate, blocked, and incubated with anti-VEGF
antibody (Dako, Carpinteria, CA, USA, M7273), anti-nephrin
(Fitzgerald, North Acton, MA, USA, 20R-NP002), and anti-
phospho-VEGFR2tyr1175 (Cell Signaling, Danvers, MA, USA,
19A10). Bound primary antibodies were visualized by immunoper-
oxidase (Dako EnVisionþ System), counterstained with hematox-
ylin, or by fluorescent-labeled (Cy2 or Cy3, Jackson Immuno-
research, West Grove, PA, USA) secondary antibodies. Cryosections
(6mm) were fixed in cold acetone, permeabilized with 0.3% Triton-
X, blocked, and incubated with primary antibodies: anti MMP-9
(ab38898, Abcam, Cambridge, MA, USA), anti-podocin (gift from P.
Mundel, University of Miami School of Medicine), anti-collagen IV
(Southern Biotech, Birmingham, AL, USA) and anti-laminin
(Sigma, St Louis, MD, USA), followed by appropriate Cy2- or
Cy3-labeled anti-rabbit, anti-mouse, or anti-goat secondary anti-
bodies. All sections were examined by confocal microscopy (FV300,
Olympus, Center Valley, PA, USA).
Transmission electron microscopy, b-Gal stain, and
immunoelectron microscopy
Kidney cortex was minced to 2mm cubes, fixed with 2%
paraformaldehyde, 2.5% glutaraldehyde in 0.1M sodium-cacodylate
buffer, postfixed with 1% OsO4 followed by 2% uranyl acetate,
dehydrated through a graded series of ethanol, and embedded
in LX112 (Ladd Research, Williston, VT, USA). Thin sections
(80 nm) were cut and stained with 0.5% uranyl acetate and 0.5%
lead citrate. For TEM b-Gal stain, kidneys were fixed and processed
for LacZ stain as described,20 postfixed as above, and processed for
TEM using standard techniques, except that uranyl acetate and lead
citrate steps were omitted, as they obscure the detection of b-Gal
precipitates.37 For immunogold labeling, kidneys were fixed with
4% paraformaldehyde and 0.05% glutaraldehyde in 0.1M sodium
cacodylate buffer and subsequently processed as for TEM and
embedded in LR-white resin (London Resin Co, Basingstoke, UK).
Sections were blocked with 0.05M glycine, followed by goat blocking
buffer (Aurion, Nl), incubated with anti-VEGFR2 polyclonal anti-
body (SC no. 315 or SC no. 504, Santa Cruz, CA, USA), incubated
with 10 nm goat anti-rabbit gold (Aurion, Wageningen, The Nether-
lands), counterstained with 0.5% uranyl acetate and 0.5% lead citrate,
and examined using a JEOL 1200EX TEM (Tokyo, Japan).
Real-time PCR
Total RNA was isolated from whole kidney cortex from podocin-
rtTA:tet-O-VEGF164 mice receiving doxycycline (TOPO þ dox,
n¼ 9) or not (TOPO dox, n¼ 8 age-matched) using Trizol
Reagent (Invitrogen, Carlsbad, CA, USA). After DNAse digestion,
reverse transcription was performed using Quantitect Reverse
Transcription Kit (Qiagen, Valencia, CA, USA). Reverse transcrip-
tion products were combined into separate pools (TOPO þ dox and
TOPO dox). Real-time PCR amplifications were performed using
SYBR-Green PCR-Master-Mix (Applied Biosystems, Foster City, CA,
USA), appropriate primers (Supplementary Table 1), and an
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Eppendorf Realplex2 Mastercycler (Hamburg, Germany). The cycle
threshold (Ct) of amplified products was detected using the
manufacturer’s software. Samples were run in duplicate and
experiments were repeated a minimum of three times. Relative
quantification was determined using the DCt method.40 Data were
normalized to glyceraldehyde-3-phosphate dehydrogenase and
expressed as fold change relative to uninduced podocin-rtTA:tet-O-
VEGF164 mice (TOPO þ dox/TOPO dox).
Immunoblotting, immunoprecipitation, and zymogram
Kidneys from age-matched podocin-rtTA:tet-O-VEGF164 mice recei-
ving doxycycline (TOPO þ dox, n¼ 13) or not (TOPO dox,
n¼ 8) were lysed in RIPA buffer þ protease inhibitors (Roche,
Indianapolis, IN, USA) þ 1mM Na3VO4 þ 1mM NaF. Protein
concentration was determined by bicinchoninic acid assay (Sigma).
Equal amount of protein lysate from individual kidneys were
combined into separate pools (þ dox and dox), and 100–150 mg
protein/lane were resolved in 8–15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Primary antibodies used for
immunoblotting were: anti-nephrin (20R-NP002, Fitzgerald); anti-
phosphorylated nephrin;31 anti-MMP-2 (Chemicon, Billerica, MA,
USA); and anti-MMP-9 (Chemicon). Anti-actin (A2066, Sigma) or
anti-tubulin (sc-58667, Santa Cruz) was used as a control for
protein loading. For nephrin and VEGFR2 immunoprecipitation
experiments, 1mg protein from whole kidney lysate was resus-
pended in immunoprecipitation buffers as described,31,41 with slight
modifications (1% Triton X-100, 1% NP-40, 0.5% deoxycholate,
10mM Tris, pH 8, 0.15M NaCl, 1mM EDTA, 50mM NaF and 1mM
Na3VO4, protease inhibitor cocktail), pre-cleared, and incubated
with polyclonal nephrin31 and VEGFR2 (sc-504, Santa Cruz)
antibodies. Some nephrin immunoprecipitation experiments were
followed by overnight incubation with 1 mg Flag-VEGFR2 protein
purified from COS cells transfected with Flag-mouse VEGFR2,
immunoblotted, and VEGFR2 was detected by anti-Flag monoclonal
antibody (Sigma). Rabbit serum was used as negative control.
Lysates from COS cells and whole kidney were used as positive
controls. Secondary antibodies were anti-rabbit or anti-mouse-
horseradish peroxidase-IgG (Amersham), detected by chemolumi-
nescence (Amersham). Kidney lysate pools (100 mg) were denatured
in sodium dodecyl sulfate buffer, resolved in zymogram gels (Novex-
Zymogram-Gel; Invitrogen), renatured, developed, and stained
following the manufacturer’s instructions. Positive control was
recombinant mouse MMP-9 (R&D). Gelatinolytic activity revealed
clear bands on a blue background.
Statistical analysis
All values are expressed as mean±s.e.m. To determine statistical
significance, we used unpaired Student’s t-test and one-way analysis
of variance for comparisons between two groups or multiple groups,
respectively. The Bonferroni correction was used to adjust for
multiple testing in quantitative PCR experiments. Mann–Whitney U-
test was used for albumin:creatinine ratios, as these data did not have
a Gaussian distribution. Po0.05 was deemed statistically significant.
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